North America Anaphylaxis Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication Type, Route of Administration, Allergy Type and Distribution Channel

Epinephrine Segment has the Largest Share of Medication Type in the North America Anaphylaxis Treatment Market during 2021-2028

According to a new market research study on “North America Anaphylaxis Treatment Market to 2028 - COVID-19 Impact and Regional Analysis and Forecast by Medication Type, Route of Administration, Allergy Type, and Distribution Channel,” is expected to reach US$ 2,891.7 million by 2028 from US$ 1,635.8 million in 2021. The market is estimated to grow at a CAGR of 8.5% from 2021 to 2028. The report provides trends prevailing in the North America anaphylaxis treatment market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising incidence of anaphylaxis and recent approvals of epinephrine are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the poor accessibility to epinephrine auto-injectors in low-income countries.

With the spread of the COVID-19 pandemic, it was discovered that a significant number of people around the world were suffering from chronic respiratory diseases, such as respiratory allergies, such as allergic rhinitis, and sinusitis. For instance, according to a survey conducted by the Asthma and Allergy Foundation of America in June 2020, stated that 2,695 people were made to participate in the study, out of which 57% have asthma, 51% have a family member with asthma, 63% have allergies, and 66% have a family member with allergies, within the survey group. Thus, the impact of COVID-19 is so far considered positive on the market. Allergy and asthma exacerbations are frequently triggered by viral infections, including coronaviruses. Thus, telehealth can be central in delivering allergy/immunology services within a risk-stratified context of the SARS-CoV-2 pandemic. Therefore, both the American Academy of Allergy, Asthma, & Immunology (AAAAI) and the American College of Allergy, Asthma, & Immunology (ACAAI) have been strong advocates to advance telehealth to allow allergy/immunology services to expand and most directly serve patients where they are needed. To provide an approach to triaging allergy/immunology services during the COVID-19 pandemic, a consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily adjust allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted, modified Delphi methodology to achieve consensus. This is likely to favor market growth.

The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel. Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others. In 2020, epinephrine segment accounted for the highest share of the market. The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children. Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.

Amneal Pharmaceuticals Inc. Mylan N.V. Adamis Pharmaceutical Corporation, Abbott, Pfizer Inc. Glaxosmithkline Plc. Merck and Co. Inc. Teva Pharmaceutical Industries Ltd. and ALK-ABELLó are among the leading companies in the North America anaphylaxis treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in December 2020, GSK Consumer Healthcare launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerin. The daily usage of the nasal spray washes out the allergens, pollutants, and debris that are trapped in the nasal passage, helping in the removal of allergy symptoms, and thus maintaining nasal hygiene.

The report segments the North America Anaphylaxis Treatment market as follows:

By Medication Type

• Epinephrine
• Antihistamines
• Steroids
• Beta-Agonist
• Others

By Route of Administration

• Parenteral
• Oral
• Others

By Allergy Type

• Food Allergy
• Medications
• Insect Stings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• North America
• US
• Canada
• Mexico

Reasons to buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America anaphylaxis treatment market
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the North America anaphylaxis treatment market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the anaphylaxis treatment market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution